GNCAQ Projected Dividend Yield

Genocea Biosciences Inc ( OTCBB : GNCAQ )

Genocea Biosciences is a biopharmaceutical company that discovers and develops cancer immunotherapies using its proprietary ATLAS™ platform. The ATLAS platform can profile each patient's CD4+ and CD8+ T cell immune responses to every potential target or antigen identified by sequencing of that patient's tumor. GEN-011 is an investigational solid tumor cell therapy candidate comprised of CD4+ and CD8+ neoantigen-targeted peripheral T cells. GEN-011 is comprised of T cells extracted from the patient's peripheral blood and specific for ATLAS-prioritized neoantigens. GEN-009 is an investigational neoantigen vaccine delivering adjuvanted synthetic long peptides from ATLAS-identified neoantigens.

20 YEAR PERFORMANCE RESULTS